Sponsor

Luye Pharma Group Ltd.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Luye Pharma Group Ltd. appears in 47 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials47
Recruiting shown3
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

47 shown
A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020NCT07230652 · lead sponsor · 2025-08-20
RECRUITING
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLCNCT06496048 · lead sponsor · 2024-09-14
RECRUITING
Study of LY01610 in Patients With Recurrent Small Cell Lung CancerNCT06128837 · lead sponsor · 2024-03-03
RECRUITING
A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With SchizophreniaNCT07396870 · lead sponsor · 2026-03-31
NOT_YET_RECRUITING
To Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Food Effects of LY03021 in Healthy Chinese SubjectsNCT07371065 · lead sponsor · 2025-10-28
ENROLLING_BY_INVITATION
A Food Effect Study of LY03020 in Healthy SubjectsNCT07292233 · lead sponsor · 2025-07-30
ACTIVE_NOT_RECRUITING
A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017NCT06980207 · lead sponsor · 2025-05-01
NOT_YET_RECRUITING
Effect of Food and Age on the Pharmacokinetics of LY03017NCT06793995 · lead sponsor · 2025-02-01
NOT_YET_RECRUITING
A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy SubjectsNCT06556966 · lead sponsor · 2024-08-19
COMPLETED
To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release TabletsNCT06426485 · lead sponsor · 2024-05-30
NOT_YET_RECRUITING
A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017NCT06388551 · lead sponsor · 2024-05-10
UNKNOWN
Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mgNCT05856630 · lead sponsor · 2023-05-01
UNKNOWN
Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast CancerNCT06098599 · lead sponsor · 2022-05-17
COMPLETED
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective DisorderNCT05321602 · lead sponsor · 2021-09-08
COMPLETED
Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®NCT05140512 · lead sponsor · 2021-02-04
COMPLETED
to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy VolunteersNCT04593511 · lead sponsor · 2021-02-02
UNKNOWN
Relative Bioavailability of LY03010 Compared to Listed DrugNCT04922593 · lead sponsor · 2021-01-13
COMPLETED
Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®NCT05110170 · lead sponsor · 2020-10-15
COMPLETED
Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung CancerNCT04381910 · lead sponsor · 2020-09-28
COMPLETED
A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PDNCT04630860 · lead sponsor · 2020-07-07
COMPLETED
A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy VolunteersNCT04384666 · lead sponsor · 2020-06-02
COMPLETED
A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PDNCT04571164 · lead sponsor · 2020-05-11
COMPLETED
Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia PatientsNCT04572685 · lead sponsor · 2020-01-22
COMPLETED
Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®NCT04563936 · lead sponsor · 2020-01-06
COMPLETED
A Relative Bioavailability Food Effect Study of LY03005NCT03822065 · lead sponsor · 2019-01-16
COMPLETED
A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia PatientsNCT03751488 · lead sponsor · 2018-12-12
COMPLETED
A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)NCT04853407 · lead sponsor · 2018-12-05
COMPLETED
A Study to Assess Pharmacokinetic Profiles of LY03003 and NeuproNCT03733561 · lead sponsor · 2018-11-09
COMPLETED
A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD PatientsNCT04629404 · lead sponsor · 2018-11-05
COMPLETED
A Study of LY03005 vs PristiqNCT03733574 · lead sponsor · 2018-06-19
COMPLETED
Pharmacokinetic Study of LY03003 in Patients With Parkinson's DiseaseNCT03589066 · lead sponsor · 2018-05-15
COMPLETED
A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate CancerNCT03450109 · lead sponsor · 2017-12-22
COMPLETED
A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung CancerNCT03533127 · lead sponsor · 2017-11-27
UNKNOWN
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®NCT03357796 · lead sponsor · 2017-11-27
COMPLETED
A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's DiseaseNCT04045678 · lead sponsor · 2017-10-10
COMPLETED
Pilot BA Study of New LY03005 vs PristiqNCT02988024 · lead sponsor · 2016-12-07
COMPLETED
Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's DiseaseNCT02728947 · lead sponsor · 2016-05-01
COMPLETED
Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)NCT03785652 · lead sponsor · 2015-10-09
COMPLETED
Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005NCT02271412 · lead sponsor · 2014-10-01
COMPLETED
Bioavailability of LY03004 and Risperdal® Consta®NCT02091388 · lead sponsor · 2014-09-01
COMPLETED
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective DisorderNCT02186769 · lead sponsor · 2014-07-01
COMPLETED
Safety, Tolerability and Pharmacokinetics Study of LY03005NCT02055300 · lead sponsor · 2014-02-01
COMPLETED
A Study of LY03003 in Patients With Early-stage Parkinson's DiseaseNCT04044547 · lead sponsor · 2013-11-22
COMPLETED
Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's DiseaseNCT02055274 · lead sponsor · 2013-10-01
COMPLETED
A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003NCT04627155 · lead sponsor · 2013-03-15
COMPLETED
Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective DisorderNCT02055287 · lead sponsor · 2013-03-01
COMPLETED
Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's DiseaseNCT06247410 · collaborator · 2021-08-23
COMPLETED

Drugs studied in this sponsor's trials

11 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Luye Pharma Group Ltd. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
Pristiq4
topotecan2
1 ML paliperidone palmitate 156 MG/ML Prefilled Syringe [Invega]1
bevacizumab1
goserelin 10.8 MG Drug Implant [Zoladex]1
irinotecan1
lurbinectedin1
Neupro1
Pristiq RxCUI 711372 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 4 trials topotecan RxCUI 57308 · Lead sponsor in 2 linked trial(s) · 2 currently recruiting 2 trials 1 ML paliperidone palmitate 156 MG/ML Prefilled Syringe [Invega] RxCUI 858055 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial bevacizumab RxCUI 253337 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial goserelin 10.8 MG Drug Implant [Zoladex] RxCUI 211544 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial irinotecan RxCUI 51499 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial lurbinectedin RxCUI 2374729 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial Neupro RxCUI 707892 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial paliperidone palmitate RxCUI 858045 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial rotigotine RxCUI 616739 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial Zoladex RxCUI 58328 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor46
collaborator1
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.